Classes
DEA Class; Rx
Common Brand Names; Corvert
- Antidysrhythmics, III
Description
Class III antiarrhythmic agent; used IV for rapid conversion of atrial fibrillation or atrial flutter to normal sinus rhythm.
Indications
Indicated for the rapid cardioversion of recent onset atrial fibrillation or atrial flutter.
Contraindications
Hypersensitivity to drug or excipients
Adverse Effects
- Headache (4%)
- Bradycardia (2%)
- HTN (2%)
- Hypotension (2%)
- Palpitations (2%)
- QTc interval prolongation (<2%)
- Nausea (>2%)
- Heart failure
- Erythematous bollous lesions
- Nodal arrythmia
- Renal failure
- Ventricular tachycardia
- Syncope
- Heart block
- Torsades de pointes
- Potentially lethal arrhythmias: sustained polymorphic V-Tach (Torsades de Pointes), AV block
Warnings
Administer in a setting of continuous ECG monitoring and by personnel trained in treating arrhythmias such as polymorphic ventricular tachycardia
Monitor for heart block
The potential for proarrhythmia may increase with administration of this drug to patients who are being treated with drugs that prolong the QT interval, such as phenothiazines, tricyclic antidepressants, tetracyclic antidepressants, and certain antihistamine drugs (H1 receptor antagonists)
Pregnancy and Lactation
This drug should not be administered to a pregnant woman unless clinical benefit outweighs potential risk to fetus
The excretion of ibutilide into breast milk has not been studied; accordingly, breastfeeding should be discouraged during therapy with this drug
Maximum Dosage
2 mg IV (infused over at least 20 minutes).
2 mg IV (infused over at least 20 minutes).
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Ibutilide
injectable solution
- 0.1mg/mL